Company news
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) news
Arrowhead Pharmaceuticals, Inc. news releases on 6ix. Latest, Oct 7, 2026: Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program…
Press releases & updates
Arrowhead Pharmaceuticals Granted Entry in the FDA STAR Pilot Program for Plozasiran in Severe Hypertriglyceridemia
October 7, 2026
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
September 29, 2026
Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for the First Dual-Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
September 15, 2026
Arrowhead Pharmaceuticals to Participate in Upcoming September 2026 Investor Conferences
September 3, 2026
Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglyceridemia
August 30, 2026
Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress
August 24, 2026
Arrowhead Pharmaceuticals - People Living with Familial Chylomicronaemia Syndrome in Germany Have Access to REDEMPLO as a New Treatment Option to Reduce Triglycerides
August 18, 2026
People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides
August 17, 2026
Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results
August 4, 2026
Arrowhead Pharmaceuticals Acquires FDA Priority Review Voucher
August 4, 2026
Arrowhead Pharmaceuticals Completes Enrollment in Global Phase 3 YOSEMITE Study of Zodasiran for the Treatment of Homozygous Familial Hypercholesterolemia
July 27, 2026
Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia
July 22, 2026
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results
July 21, 2026
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome
June 23, 2026
Arrowhead Pharmaceuticals Receives Marketing Authorization in the European Union for REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
June 22, 2026
Arrowhead Pharmaceuticals to Host a Webinar on its Cardiometabolic Pipeline as Part I of the 2026 Summer Series of R&D Webinars
June 18, 2026
Arrowhead Pharmaceuticals to Participate in Upcoming June 2026 Events
June 2, 2026
Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026
May 27, 2026
Arrowhead Pharmaceuticals Presents New Positive Clinical Cardiometabolic Data at the 94th European Atherosclerosis Society (EAS) Congress
May 26, 2026
Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
May 7, 2026
Arrowhead Pharmaceuticals Licenses Clinical MASH Program Targeting PNPLA3 to Madrigal Pharmaceuticals
May 4, 2026
Arrowhead Pharmaceuticals to Participate in Upcoming May 2026 Events
May 4, 2026
Arrowhead Pharmaceuticals Receives TGA Approval of REDEMPLO® (plozasiran) in Australia, Expanding Global Access for Patients with Familial Chylomicronemia Syndrome (FCS)
May 1, 2026
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome in Europe
April 27, 2026
Arrowhead Pharmaceuticals Receives Positive CHMP Opinion Recommending Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS) in Europe
April 24, 2026
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Second Quarter Results
April 20, 2026
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology's 75th Annual Scientific Session and Expo
March 30, 2026
Arrowhead Pharmaceuticals Presents New Long-Term Efficacy and Safety Data for Plozasiran Across a Spectrum of Hypertriglyceridemia at the American College of Cardiology’s 75th Annual Scientific Session and Expo
March 27, 2026
Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
February 24, 2026
ARWR: Strong Start for REDEMPLO Commercialization…
February 11, 2026
Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
February 5, 2026
Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
February 4, 2026
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
January 27, 2026
Arrowhead Pharmaceuticals to Webcast Fiscal 2026 First Quarter Results
January 20, 2026
Arrowhead Pharmaceuticals Prices Upsized Offerings of Convertible Senior Notes, Common Stock and Pre-Funded Warrants
January 7, 2026
Arrowhead Pharmaceuticals Announces NMPA Approval of REDEMPLO® (plozasiran) for Familial Chylomicronemia Syndrome (FCS) in China
January 7, 2026
Arrowhead Pharmaceuticals Announces Proposed Offerings of Convertible Senior Notes and Common Stock
January 6, 2026
Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates Showing Weight Loss in Obese Patients with Diabetes and Improved Measures of Body Composition
January 6, 2026
Arrowhead Pharmaceuticals Announces Health Canada Approval of REDEMPLO™ (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
January 4, 2026
Arrowhead Pharmaceuticals to Participate in Upcoming January 2026 Events
December 22, 2025
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
December 14, 2025
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
December 7, 2025
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran in Severe Hypertriglyceridemia
December 1, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming December 2025 Conferences
November 30, 2025
Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
November 24, 2025
Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics
November 23, 2025
ARWR: REDEMPLO® Approved by FDA for the Treatment of FCS…
November 19, 2025
Arrowhead Pharmaceuticals Announces FDA Approval of REDEMPLO® (plozasiran) to Reduce Triglycerides in Adults with Familial Chylomicronemia Syndrome (FCS)
November 17, 2025
Arrowhead Pharmaceuticals to Webcast Fiscal 2025 Year-End Results
November 5, 2025
Arrowhead Pharmaceuticals to Participate in Upcoming November 2025 Conferences
November 3, 2025